Media stories about Gilead Sciences (NASDAQ:GILD) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gilead Sciences earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 45.6717814055713 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s analysis:
- [$$] U.K. Health Service Turns to Clinical Trial to Make Cheaper HIV Drug Available (finance.yahoo.com)
- [$$] England Turns to Clinical Trial to Get HIV Drug for Less (finance.yahoo.com)
- Short Interest in Gilead Sciences, Inc. (GILD) Grows By 25.9% (americanbankingnews.com)
- Gilead Sciences, Inc.’s HIV-1 Treatment Granted Priority Review (smarteranalyst.com)
- These Managers Like Big Bets (finance.yahoo.com)
A number of brokerages recently issued reports on GILD. BidaskClub lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday. BMO Capital Markets reaffirmed a “hold” rating and issued a $76.00 price objective (up previously from $75.00) on shares of Gilead Sciences in a report on Wednesday, May 3rd. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price objective on shares of Gilead Sciences in a report on Wednesday, July 5th. Morgan Stanley reaffirmed an “equal weight” rating on shares of Gilead Sciences in a report on Tuesday, July 11th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Twelve analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $80.31.
Gilead Sciences (NASDAQ:GILD) opened at 72.40 on Friday. The firm’s 50-day moving average price is $72.36 and its 200 day moving average price is $68.77. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $82.10. The firm has a market capitalization of $94.55 billion, a price-to-earnings ratio of 7.86 and a beta of 1.21.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter in the prior year, the firm earned $3.08 EPS. The business’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, analysts predict that Gilead Sciences will post $8.76 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s payout ratio is presently 22.58%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $71.00, for a total value of $5,206,643.00. Following the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the sale, the executive vice president now owns 106,113 shares in the company, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 206,666 shares of company stock valued at $15,223,184. Insiders own 1.30% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.